Q1 EPS Forecast for Stoke Therapeutics Increased by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Wedbush lifted their Q1 2025 EPS estimates for shares of Stoke Therapeutics in a report issued on Tuesday, March 18th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.57) per share for the quarter, up from their previous estimate of ($0.58). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.37) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($3.13) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($2.01) EPS.

Other research analysts also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Chardan Capital restated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Stock Down 2.2 %

Shares of STOK opened at $8.15 on Friday. Stoke Therapeutics has a twelve month low of $6.29 and a twelve month high of $17.58. The stock has a market capitalization of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99. The company has a 50 day moving average of $9.47 and a 200-day moving average of $11.42.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently bought and sold shares of STOK. KLP Kapitalforvaltning AS bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics in the fourth quarter valued at approximately $113,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $124,000. Tower Research Capital LLC TRC grew its position in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after buying an additional 4,918 shares during the period. Finally, Invesco Ltd. acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.